GlassScriptPhysician profile
Nicolae Weisz
NPI 1538260476
$5,990.02
in general payments reported to CMS, 2019-2025
31 companies · $1,688 in 2025
The $1,688 reported for 2025 was more than what 75% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $612 · 2020: $313 · 2021: $274 · 2022: $1,360 · 2023: $907 · 2024: $836 · 2025: $1,688.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,316 · Education: $115.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,316.09 |
| Education | $115.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,117.80 | 2019-2025 | Skyrizi, Rinvoq, Linzess |
| Janssen Biotech, INC. | $1,006.34 | 2020-2025 | Tremfya, Stelara, Simponi Aria |
| Gilead Sciences, INC. | $295.69 | 2024-2025 | Livdelzi |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $255.85 | 2019-2025 | Xifaxan |
| Celgene Corporation | $251.59 | 2022-2024 | Zeposia |
| Pfizer INC. | $242.59 | 2025 | |
| Madrigal Pharmaceuticals | $242.44 | 2024-2025 | Rezdiffra, Resmetirom |
| Genzyme Corporation | $173.86 | 2022-2024 | |
| Merck Sharp & Dohme LLC | $169.81 | 2019-2023 | Dificid |
| Takeda Pharmaceuticals U.S.A., INC. | $163.29 | 2019-2024 | Gattex, Eohilia |
| Celltrion USA INC. | $148.90 | 2025 | Zymfentra, Vegzelma |
| Thd America, INC. | $123.76 | 2019 | |
| Janssen Scientific Affairs, LLC | $123.55 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $64.33 | 2022-2024 | Dupixent |
| Nestle Healthcare Nutrition INC. | $63.91 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $59.10 | 2023-2025 | Omvoh |
| Intercept Pharmaceuticals, INC. | $53.40 | 2022-2024 | |
| Ironwood Pharmaceuticals, INC | $48.63 | 2021-2022 | |
| Redhill Biopharma INC. | $44.70 | 2021-2023 | |
| Boston Scientific Corporation | $43.13 | 2019 | |
| Aimmune Therapeutics, INC. | $41.77 | 2024-2025 | Zenpep |
| Novo Nordisk INC | $38.48 | 2025 | Wegovy |
| Braintree Laboratories, INC. | $36.17 | 2021-2023 | Sutab |
| Shionogi INC | $35.60 | 2019 | |
| Orphalan INC | $33.46 | 2024 | Cuvrior |
| Qol Medical, LLC | $24.57 | 2019 | |
| Intra-Sana Laboratories | $21.33 | 2021 | |
| Ardelyx, INC. | $18.91 | 2023 | Ibsrela |
| Ferring Pharmaceuticals INC. | $18.81 | 2022 | |
| Shire North American Group INC | $17.30 | 2019 | |
| Daiichi Sankyo INC. | $10.95 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nicolae Weisz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.